CSTL - Public offerings

Stokes was one of 22 financial leaders recognized in the Greater Houston areaFRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is among 22 chief financial officers from across the Greater Houston area recognized for their financial leadership and contributions to their organizations' success. Honorees will be celebrated a

Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021 Full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2022. "In 2022, we delivered strong year-over-year growth in revenue and test report volume, reflecting solid execution by our Castle team," said Derek Maetzold, president and chief executive o

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing's Top 25 CFOs of Houston list for 2023. This year's awardees are financial executives at the forefront of the rapid technological development occurring throughout Houston across key global industries, including energy, life sciences, manufacturing, logistics and aerospace. "I am proud of Frank's accomplishments at Castle," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We believe his recognition among Houston's Top 25 CFOs is a testament to his

Q3 2022 revenue grew by 58% over Q3 2021 to $37.0 million Delivered 12,114 total test reports in Q3 2022, an increase of 57% compared to Q3 2021 Foundational guideposts and three-year financial targets presented at Investor Day in September Further increasing 2022 revenue guidance to $132-137 million from $130-135 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2022. "We achieved strong top-line growth and a new record in total quarterly test report volume, which we bel

Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021 Skin cancer gene expression profile test report volume increased 44% compared to Q2 2021 Raising 2022 Revenue Guidance to $130–135 million from $118–123 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2022. "In the second quarter, we saw strong execution across the Castle team, which produced another quarter of record test report

Q1 2022 revenue increased 18% over Q1 2021 to $26.9 million Q1 2022 adjusted revenue increased 50% over Q1 2021 to $26.3 million Delivered 8,627 total test reports in Q1 2022, an increase of 68% compared to Q1 2021 DecisionDx-Melanoma test report volume increased 48% over Q1 2021 Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2022. "We saw significant progress and execution on our growth initiatives in the first quarter, with record test report volume," said Derek Maetzold, president and chief ex

Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume Full-year 2022 revenue is expected to be between $115-120 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021. "Driven by our patient-centric focus and our commitment to strong execution on our growth plans, we had an outstanding 2021," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We exceeded the

Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to inform disease management and improve patient outcomes, today announced its financial results for the third quarter and nine months ended Sept. 30, 2021. "The Castle team achieved another quarter of strong growth in revenue and test report volume, despite the diagnoses of cutaneous melanoma being down by approximately 16% compared to historical pre-COVID third quarte

Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539 DecisionDx-Melanoma test reports increased 70%, compared to Q2 2020 Raising 2021 Revenue Guidance to $89-93 million from $80-83 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, today announced its financial results for the second quarter and six months ended June 30, 2021. "The Castle team delivered an exceptional quarter, which included record test report volume across each of our gene expression profile

Q1 2021 revenues of $22.8 million, compared to $17.4 million in Q1 2020 Q1 2021 total dermatology test report volume of 4,805 Initiates 2021 Revenue Guidance of $80-83 million Q1 2021 gross margin of 87% Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, today announced its financial results for the first quarter ended March 31, 2021. "We are pleased with our strong execution in the first quarter, with revenue increasing by 31% over the first quarter of 2020," said Derek Maetzold, president and chief executive officer of Castle Bioscience

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020. “At Castle, we are committed to providing innovative, clinically actionable dermatologic tests to improve patient outcomes,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “In 2020, despite the challenges presented to us all by the global pandemic, our team remained focused on this commitment and performed exceptionally. “We delivered year-over-ye

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share. The gross proceeds to Castle from the offering, including the shares sold pursuant to the underwriters’ option, before deducting the underwriting discounts and commissions and other offering expenses payable by Castle, were $266.8 million. SVB Leerink and Baird acted as joint bookrunning managers in the offering. Canaccord Genu

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to Castle from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Castle, are expected to be $232 million. In addition, Castle has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 18, 2020, subject to customa

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell $125,000,000 of shares of its common stock. In connection with the offering, Castle expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock. All of the shares in the proposed offering will be offered by Castle. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Leerink and Baird are acting as joint bookrunning managers in the